Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Aug 01, 2018 6:43am

303 Views

Post# 28396110

RE:Approaching 5 months since approval

longterm56 wrote:
As we enter the beginning of August, we are quickly approaching 5 months after FDA approval. Considering that TH was preparing their sales force for close to a year *before* approval, I am quite dissappointed in the progress. Just how long does this "amazing" return take? -LT

I suggets you go back and listen to the conference call held just after approval.

Luc mentioned that it often takes 6 months to get coverage for the drug in place. Right out of the gate, TH did well with coverage but there should be more to come.

bfw

Bullboard Posts

Soma Gold poised to extend profitable track record